Immatics
Biotechnology ResearchBaden-württemberg, Germany501-1000 Employees
Immatics is a biotechnology company focused on cancer research and therapies, based in Tübingen, Baden-Württemberg. It describes itself as a global leader in precision targeting of PRAME, an antigen expressed across more than 50 cancers. Its portfolio spans TCR T-cell therapies and TCR bispecifics, creating a broad PRAME-centered program with multiple indications and modalities. Its work targets patients with cancer seeking new treatment options through PRAME-targeted therapies. In 2026, Immatics presented extended data from the ongoing anzu-cel PRAME TCR T-cell therapy trial at ASCO, highlighting rapid and durable anti-tumor activity and noting the Phase 3 trial remains on track toward regulatory submission.
1-888-653-2347 
support@leadiq.com 
